» Articles » PMID: 26442957

Validation of the Revised Mystical Experience Questionnaire in Experimental Sessions with Psilocybin

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2015 Oct 8
PMID 26442957
Citations 177
Authors
Affiliations
Soon will be listed here.
Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants (n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a "complete mystical experience" that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.

Citing Articles

The Gateway Experience Facilitates Psychological Well-Being.

Fabrizi P, Ditye T Integr Psychol Behav Sci. 2025; 59(1):34.

PMID: 40080317 DOI: 10.1007/s12124-025-09901-y.


The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.

Strickland J, Garcia-Romeu A, Johnson M Psychedelic Med (New Rochelle). 2025; 2(1):33-43.

PMID: 40051759 PMC: 11658653. DOI: 10.1089/psymed.2023.0046.


Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.

Weintraub M, Jeffrey J, Grob C, Ichinose M, Bergman R, Cooper Z Psychedelic Med (New Rochelle). 2025; 1(4):230-240.

PMID: 40046861 PMC: 11658652. DOI: 10.1089/psymed.2023.0018.


Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics.

Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D Psychedelic Med (New Rochelle). 2025; 1(2):74-86.

PMID: 40046726 PMC: 11658661. DOI: 10.1089/psymed.2023.0010.


On the varieties of conscious experiences: Altered Beliefs Under Psychedelics (ALBUS).

Safron A, Juliani A, Reggente N, Klimaj V, Johnson M Neurosci Conscious. 2025; 2025(1):niae038.

PMID: 39949786 PMC: 11823823. DOI: 10.1093/nc/niae038.


References
1.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

2.
Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

3.
Garcia-Romeu A, Griffiths R, Johnson M . Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2015; 7(3):157-64. PMC: 4342293. DOI: 10.2174/1874473708666150107121331. View

4.
Johnson M, Garcia-Romeu A, Cosimano M, Griffiths R . Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014; 28(11):983-92. PMC: 4286320. DOI: 10.1177/0269881114548296. View

5.
Griffiths R, Richards W, McCann U, Jesse R . Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006; 187(3):268-83. DOI: 10.1007/s00213-006-0457-5. View